173 related articles for article (PubMed ID: 15150304)
1. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
[TBL] [Abstract][Full Text] [Related]
2. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Ishida T; Kiba T; Takeda M; Matsuyama K; Teramukai S; Ishiwata R; Masuda N; Takatsuka Y; Noguchi S; Ishioka C; Fukushima M; Ohuchi N
Cancer Chemother Pharmacol; 2009 Jul; 64(2):361-9. PubMed ID: 19082596
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
Redana S; Donadio M; Nolè F; Jacomuzzi ME; Beano A; Martinello R; Sapino A; Viale G; Aglietta M; Montemurro F
BMC Cancer; 2010 Feb; 10():28. PubMed ID: 20122160
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
Arteaga CL; O'Neill A; Moulder SL; Pins M; Sparano JA; Sledge GW; Davidson NE
Clin Cancer Res; 2008 Oct; 14(19):6277-83. PubMed ID: 18829509
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Verschoor N; Bos MK; de Kruijff IE; Van MN; Kraan J; Drooger JC; Zuetenhorst JM; Wilting SM; Sleijfer S; Jager A; Martens JWM
Breast Cancer Res Treat; 2024 May; 205(1):87-95. PubMed ID: 38291268
[TBL] [Abstract][Full Text] [Related]
7. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Ross JS; Slodkowska EA; Symmans WF; Pusztai L; Ravdin PM; Hortobagyi GN
Oncologist; 2009 Apr; 14(4):320-68. PubMed ID: 19346299
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D; Wesolowski R; Zelinskas S; Pinette A; Benner B; Schwarz E; Savardekar H; Johnson C; Stiff A; Yu L; Macrae E; Lustberg M; Mrozek E; Ramaswamy B; Carson WE
Cancer Control; 2024; 31():10732748241250189. PubMed ID: 38797949
[TBL] [Abstract][Full Text] [Related]
9. Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
Gomez Marti JL; Nasrazadani A; Ding Y; Normolle D; Brufsky AM
Oncologist; 2023 Nov; 28(11):e1123-e1126. PubMed ID: 37725049
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.
Wolff AC; Wang M; Li H; Pins MR; Pretorius FJ; Rowland KM; Sparano JA; Davidson NE
Breast Cancer Res Treat; 2010 May; 121(1):111-20. PubMed ID: 20333545
[TBL] [Abstract][Full Text] [Related]
11. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Extra JM; Antoine EC; Vincent-Salomon A; Delozier T; Kerbrat P; Bethune-Volters A; Guastalla JP; Spielmann M; Mauriac L; Misset JL; Serin D; Campone M; Hebert C; Remblier C; Bergougnoux L; Campana F; Namer M
Oncologist; 2010; 15(8):799-809. PubMed ID: 20671105
[TBL] [Abstract][Full Text] [Related]
13. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
Cheng H; Ballman K; Vassilakopoulou M; Dueck AC; Reinholz MM; Tenner K; Gralow J; Hudis C; Davidson NE; Fountzilas G; McCullough AE; Chen B; Psyrri A; Rimm DL; Perez EA
Br J Cancer; 2014 Sep; 111(6):1065-71. PubMed ID: 25117817
[TBL] [Abstract][Full Text] [Related]
14. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.
Bartsch R; Wenzel C; Hussian D; Pluschnig U; Sevelda U; Koestler W; Altorjai G; Locker GJ; Mader R; Zielinski CC; Steger GG
BMC Cancer; 2006 Mar; 6():63. PubMed ID: 16539726
[TBL] [Abstract][Full Text] [Related]
15. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
[TBL] [Abstract][Full Text] [Related]
16. Toxic Cardiomyopathy in a Young Patient Treated for Her2-Positive Early Breast Cancer: Case Report and Literature Review.
Hadžibeganović A; Koprić D
Acta Med Acad; 2023 Dec; 52(3):225-230. PubMed ID: 38095178
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).
Hirai I; Tanese K; Nakamura Y; Fukuda K; Ouchi T; Hayashida T; Kameyama K; Abe T; Amagai M; Funakoshi T
Oncologist; 2024 Jun; ():. PubMed ID: 38823035
[TBL] [Abstract][Full Text] [Related]
18. Survival after Trastuzumab Therapy in Patients with Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of Randomized Controlled Trials.
Ali MD; Al-Matouq JA; Ahmad A; Patel M; Alshnbari AS; Alhussini SH; Almozien SF; Alowaywi GA; Kannan LS
J Pharm Bioallied Sci; 2024; 16(1):24-30. PubMed ID: 38694962
[TBL] [Abstract][Full Text] [Related]
19. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
Taube SE; Clark GM; Dancey JE; McShane LM; Sigman CC; Gutman SI
J Natl Cancer Inst; 2009 Nov; 101(21):1453-63. PubMed ID: 19855077
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for response to docetaxel in human breast cancers.
Noguchi S
Cancer Sci; 2006 Sep; 97(9):813-20. PubMed ID: 16805818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
